Codexis - CDXS Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings or view top-rated stocks.

3 analysts have issued 12 month target prices for Codexis' stock. Their CDXS share price forecasts range from $9.00 to $23.00. On average, they anticipate the company's stock price to reach $18.83 in the next twelve months. This suggests a possible upside of 376.8% from the stock's current price.
View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts.

Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 15.2% and is now trading at $3.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CDXS earnings forecast.

Codexis, Inc. (NASDAQ:CDXS) released its earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company earned $30.40 million during the quarter, compared to analyst estimates of $28.92 million. Codexis had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 21.78%. The business's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) EPS.

ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA) and iShares Biotechnology ETF (IBB).

Codexis updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$68.00 million, compared to the consensus revenue estimate of $91.98 million.

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (9.42%), Nantahala Capital Management LLC (6.83%), ARK Investment Management LLC (6.00%), Telemark Asset Management LLC (3.96%), Geode Capital Management LLC (1.81%) and Sumitomo Mitsui Trust Holdings Inc. (1.66%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Patrick Y Yang, Stephen George Dilly and Thomas R Baruch.
View institutional ownership trends.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $3.95.

Codexis (NASDAQ:CDXS) has a market capitalization of $260.49 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

The company employs 261 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.